Esperion Therapeutics, Inc.ESPRNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +114.30% | -52.81% | +11.58% | +69.10% | +143.73% |
| Gross Profit Growth | +109.07% | -73.79% | -7.53% | -7.15% | +223.33% |
| EBITDA Growth | +0.00% | -127.96% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | -130.57% | +175.11% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | -166.30% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | -158.33% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | -161.76% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +73.99% | +15.87% | +4.26% | +1.65% | +21.02% |
| Weighted Average Shares Diluted Growth | +73.99% | +3.42% | +4.26% | +1.65% | +45.51% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | -142.04% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | -142.09% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +65.26% | +48.86% | +78.51% | +75.42% | +74.93% |
| Inventory Growth | +43.99% | +35.88% | +35.51% | +77.07% | +11.25% |
| Asset Growth | +67.07% | -13.14% | -1.49% | +15.89% | +35.50% |
| Book Value per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Debt Growth | -44.98% | -45.75% | +122.26% | +123.45% | +84.14% |
| R&D Expense Growth | -38.13% | -6.31% | -36.85% | +35.91% | +26.87% |
| SG&A Expenses Growth | -18.71% | +2.40% | -10.58% | +4.69% | +12.21% |